Detection_NN of_IN Human_NP Papillomavirus_NP DNA_NP in_IN Urine_NP Specimens_NP from_IN Human_NP Immunodeficiency_NN Virus-Positive_NP Women_NP Human_NP immunodeficiency_NN virus_NN (HIV)-positive_JJ women_NNS may_MD represent_VB one_CD of_IN the_DT fastest-growing_JJ populations_NNS at_IN risk_NN for_IN acquiring_VBG cervical_JJ cancer_NN and_CC thus_RB require_VB frequent_JJ screening_NN ._SENT The_DT purpose_NN of_IN the_DT present_JJ studies_NNS was_VBD to_TO validate_VB a_DT PCR-based_JJ urine_NN assay_NN by_IN comparing_VBG detection_NN and_CC genotyping_NN of_IN human_JJ papillomavirus_NNS (_( HPV_NP )_) DNA_NN in_IN urine_NN samples_NNS and_CC matching_VBG cervical_JJ swab_NN specimens_NNS of_IN HIV-positive_JJ women_NNS ._SENT Despite_IN a_DT difference_NN in_IN amplifiability_NN ,_, the_DT prevalence_NN of_IN any_DT HPV_NP genotype_NN (_( 58_CD %_NN for_IN the_DT cervical_JJ swab_NN specimens_NNS and_CC 48_CD %_NN for_IN the_DT urine_NN specimens_NNS )_) was_VBD not_RB significantly_RB different_JJ in_IN this_DT population_NN ._SENT The_DT levels_NNS of_IN concordance_NN were_VBD 70_CD ,_, 71_CD ,_, and_CC 78_CD %_NN for_IN detection_NN of_IN any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, or_CC any_DT low-risk_JJ HPV_NP type_NN in_IN the_DT two_CD specimen_NN types_NNS ,_, respectively_RB ._SENT While_IN instances_NNS of_IN discordant_JJ detection_NN were_VBD greater_JJR for_IN the_DT cervical_JJ swab_NN specimens_NNS than_IN for_IN the_DT urine_NN specimens_NNS ,_, this_DT was_VBD not_RB statistically_RB significant_JJ ._SENT The_DT distributions_NNS of_IN HPV_NP genotypes_NNS were_VBD similar_JJ in_IN the_DT cervix_NN and_CC the_DT urine_NN for_IN the_DT majority_NN of_IN types_NNS examined_VBD ._SENT Importantly_RB ,_, detection_NN of_IN HPV_NP DNA_NP in_IN urine_NN was_VBD associated_VBN with_IN an_DT abnormal_JJ Papanicolaou_NP smear_NN to_TO the_DT same_JJ extent_NN that_IN detection_NN of_IN HPV_NP DNA_NP in_IN a_DT cervical_JJ swab_NN specimen_NN was_VBD ._SENT These_DT data_NNS provide_VBP preliminary_JJ support_NN for_IN the_DT proposal_NN to_TO use_VB urine_NN testing_NN as_IN a_DT primary_JJ or_CC secondary_JJ screening_VBG tool_NN for_IN cervical_JJ cancer_NN in_IN HIV-positive_JJ women_NNS or_CC as_IN an_DT epidemiological_JJ tool_NN ._SENT Additional_JJ studies_NNS with_IN larger_JJR sample_NN sizes_NNS must_MD be_VB conducted_VBN in_IN order_NN to_TO further_RBR verify_VB these_DT findings_NNS ._SENT Human_NP papillomavirus_NP (_( HPV_NP )_) is_VBZ the_DT cause_NN of_IN the_DT most_RBS common_JJ sexually_RB transmitted_VBN diseases_NNS (_( STDs_NP )_) of_IN viral_JJ etiology_NN worldwide_RB ._SENT Approximately_RB 30_CD to_TO 50_CD %_NN of_IN the_DT general_JJ population_NN is_VBZ positive_JJ for_IN HPV_NP DNA_NP ._SENT At_IN least_JJS 30_CD known_JJ HPV_NP types_NNS infect_VBP the_DT anogenital_JJ region_NN (_( ;_: Los_NP Alamos_NP National_NP Laboratory_NP HPV_NP Sequence_NP Database_NP ,_, 2001_CD )_) ._SENT These_DT types_NNS are_VBP classified_VBN as_IN being_VBG of_IN low_JJ ,_, intermediate_JJ ,_, or_CC high_JJ risk_NN on_IN the_DT basis_NN of_IN their_PP$ in_IN vitro_NN abilities_NNS to_TO cause_VB cellular_JJ transformation_NN and_CC their_PP$ clinical_JJ association_NN with_IN cervical_JJ cancer_NN ._SENT High-risk_JJ HPV_NP types_NNS ,_, like_IN HPV_NP types_NNS 16_CD ,_, 18_CD ,_, 31_CD ,_, and_CC 45_CD ,_, are_VBP more_RBR closely_RB associated_VBN with_IN anogenital_JJ malignancies_NNS and_CC have_VBP been_VBN implicated_VBN in_IN the_DT etiology_NN of_IN most_JJS ,_, if_IN not_RB all_RB ,_, cervical_JJ cancers_NNS ._SENT Cervical_JJ cancer_NN is_VBZ the_DT second_JJ most_RBS common_JJ cancer_NN of_IN women_NNS worldwide_RB ._SENT Importantly_RB ,_, infection_NN with_IN HPV_NP ,_, even_RB high-risk_JJ types_NNS ,_, is_VBZ asymptomatic_JJ in_IN most_JJS people_NNS and_CC usually_RB does_VBZ not_RB lead_VB to_TO cancer_NN ._SENT However_RB ,_, more_JJR than_IN 35_CD HPV_NP types_NNS have_VBP been_VBN found_VBN to_TO be_VB associated_VBN with_IN at_IN least_JJS 90_CD %_NN of_IN cases_NNS of_IN cervical_JJ intraepithelial_JJ neoplasia_NN ,_, which_WDT is_VBZ a_DT precursor_NN lesion_NN to_TO cervical_JJ cancer_NN ._SENT Although_IN the_DT medical_JJ standard_NN for_IN the_DT diagnosis_NN of_IN HPV_NP disease_NN is_VBZ the_DT Papanicolaou_NP (_( Pap_NN )_) smear_NN ,_, screening_VBG by_IN this_DT type_NN of_IN method_NN has_VBZ inherent_JJ problems_NNS ._SENT Only_RB 15_CD to_TO 50_CD %_NN of_IN patients_NNS with_IN HPV_NP infections_NNS are_VBP accurately_RB identified_VBN by_IN Pap_NN smears_NNS ._SENT Additionally_RB ,_, the_DT efficacy_NN of_IN screening_NN by_IN use_NN of_IN the_DT Pap_NN smear_NN relies_VBZ on_IN repeated_JJ (_( yearly_JJ )_) visits_NNS ._SENT Approximately_RB 10_CD %_NN of_IN women_NNS in_IN the_DT United_NP States_NPS have_VBP never_RB had_VBN a_DT Pap_NN smear_NN ,_, and_CC about_RB 30_CD %_NN of_IN women_NNS do_VBP not_RB have_VB them_PP on_IN a_DT regular_JJ basis_NN ._SENT Furthermore_RB ,_, Pap_NN smear_NN screening_NN requires_VBZ a_DT pelvic_JJ examination_NN ,_, which_WDT is_VBZ invasive_JJ and_CC uncomfortable_JJ for_IN the_DT patient_NN as_IN well_RB as_RB time-consuming_JJ for_IN the_DT health_NN care_NN provider_NN ._SENT Perhaps_RB the_DT use_NN of_IN urine_NN sampling_NN for_IN routine_JJ detection_NN of_IN HPV_NP could_MD provide_VB a_DT preliminary_JJ screen_NN for_IN cervical_JJ cancer_NN and_CC thus_RB circumvent_VB the_DT need_NN for_IN an_DT annual_JJ Pap_NN smear_NN for_IN women_NNS who_WP are_VBP negative_JJ for_IN HPV_NP DNA_NP ._SENT Alternatively_RB ,_, detection_NN of_IN HPV_NP DNA_NP in_IN urine_NN could_MD possibly_RB function_VB as_IN a_DT secondary_JJ screening_NN technique_NN for_IN cervical_JJ cancer_NN in_IN that_WDT it_PP could_MD be_VB used_VBN to_TO triage_NN women_NNS with_IN atypical_JJ squamous_JJ cells_NNS of_IN undetermined_JJ significance_NN (_( ASCUS_NP )_) ._SENT Methods_NNS for_IN the_DT detection_NN of_IN DNA_NN in_IN patient_JJ urine_NN have_VBP recently_RB been_VBN used_VBN to_TO diagnose_VB other_JJ common_JJ STDs_NNS that_WDT affect_VBP the_DT cervix_NN ,_, such_JJ as_IN Chlamydia_NP trachomatis_NP and_CC Neisseria_NP gonorrhoeae_NNS infections_NNS ._SENT The_DT success_NN of_IN these_DT screening_NN programs_NNS provides_VBZ a_DT good_JJ preliminary_JJ endorsement_NN of_IN attempts_NNS to_TO monitor_VB cervical_JJ pathology_NN by_IN detecting_VBG HPV_NP DNA_NP in_IN urine_NN specimens_NNS ._SENT One_CD advantage_NN to_TO the_DT detection_NN of_IN these_DT organisms_NNS and_CC the_DT detection_NN of_IN HPV_NP from_IN urine_NN specimens_NNS may_MD be_VB that_IN a_DT single_JJ specimen_NN could_MD perhaps_RB be_VB used_VBN to_TO detect_VB all_DT three_CD of_IN these_DT infectious_JJ agents_NNS simultaneously_RB ._SENT Several_JJ investigators_NNS have_VBP attempted_VBN to_TO use_VB urine_NN sampling_NN for_IN HPV_NP DNA_NP detection_NN ;_: however_RB ,_, no_DT study_NN to_TO date_NN has_VBZ addressed_VBN the_DT ability_NN to_TO detect_VB HPV_NP DNA_NP in_IN the_DT urine_NN of_IN human_JJ immunodeficiency_NN virus_NN (HIV)-positive_JJ women_NNS ._SENT HIV-positive_JJ women_NNS demonstrate_VBP increased_VBN rates_NNS of_IN new_JJ HPV_NP infections_NNS ,_, persistence_NN of_IN high-risk_JJ HPV_NP infections_NNS ,_, multiple_JJ infections_NNS ,_, dysplasia_NN ,_, and_CC cervical_JJ cancer_NN ._SENT Furthermore_RB ,_, once_RB cervical_JJ cancer_NN develops_VBZ in_IN these_DT women_NNS ,_, the_DT disease_NN tends_VBZ to_TO be_VB more_RBR aggressive_JJ and_CC less_RBR responsive_JJ to_TO treatment_NN ._SENT In_IN consideration_NN of_IN these_DT factors_NNS ,_, the_DT importance_NN of_IN cervical_JJ cancer_NN screening_NN in_IN this_DT population_NN is_VBZ evident_JJ ._SENT The_DT current_JJ strategy_NN for_IN baseline_JJ screening_NN of_IN HIV-positive_JJ women_NNS with_IN normal_JJ cervical_JJ cytology_NN is_VBZ to_TO repeat_VB Pap_NN smear_NN testing_VBG every_DT 6_CD months_NNS ._SENT The_DT detection_NN of_IN HPV_NP DNA_NP in_IN the_DT urine_NN of_IN HIV-positive_JJ women_NNS could_MD identify_VB women_NNS at_IN risk_NN for_IN HPV_NP disease_NN in_IN a_DT routine_JJ manner_NN that_WDT is_VBZ less_RBR invasive_JJ to_TO the_DT patient_NN ._SENT The_DT purpose_NN of_IN the_DT studies_NNS described_VBD here_RB was_VBD to_TO validate_VB the_DT urine-based_JJ HPV_NP DNA_NP detection_NN method_NN that_WDT was_VBD developed_VBN in_IN our_PP$ laboratory_NN by_IN comparing_VBG the_DT results_NNS obtained_VBN by_IN that_DT method_NN to_TO those_DT obtained_VBN by_IN detection_NN of_IN HPV_NP DNA_NP from_IN matching_VBG cervical_JJ swab_NN specimens_NNS for_IN a_DT population_NN of_IN HIV-positive_JJ women_NNS for_IN whom_WP the_DT ability_NN to_TO access_VB cervical_JJ pathology_NN due_JJ to_TO HPV_NP infection_NN by_IN urine_NN testing_NN has_VBZ not_RB been_VBN described_VBN previously_RB ._SENT Patient_JJ population_NN ._SENT |_SYM All_NP patients_NNS included_VBD in_IN the_DT study_NN were_VBD enrolled_VBN in_IN the_DT HIV_NP Outpatient_NP Clinic_NP at_IN the_DT Medical_NP Center_NP of_IN Louisiana_NP in_IN New_NP Orleans_NP ,_, La._NP The_DT study_NN included_VBD 101_CD patients_NNS with_IN urine_NN samples_NNS and_CC matching_VBG cervical_JJ swab_NN samples_NNS ._SENT At_IN the_DT time_NN of_IN their_PP$ scheduled_VBN visit_NN ,_, which_WDT included_VBD a_DT routine_JJ Pap_NN smear_NN ,_, a_DT cervical_JJ swab_NN specimen_NN and_CC a_DT non-clean-catch_NN urine_NN specimen_NN were_VBD collected_VBN ._SENT Although_IN the_DT specimen_NN collection_NN sequence_NN was_VBD not_RB strictly_RB enforced_VBN ,_, the_DT urine_NN was_VBD usually_RB collected_VBN prior_RB to_TO the_DT pelvic_JJ examination_NN ._SENT All_DT study_NN participants_NNS signed_VBD informed_JJ consents_NNS ,_, and_CC the_DT study_NN was_VBD approved_VBN by_IN the_DT Louisiana_NP State_NP University_NP Health_NP Sciences_NPS Center_NP Institutional_NP Review_NP Board_NP in_IN compliance_NN with_IN federally_RB regulated_VBN guidelines_NNS for_IN research_NN involving_VBG human_JJ subjects_NNS ._SENT Both_DT cervical_JJ swab_NN and_CC urine_NN specimens_NNS from_IN all_DT 101_CD patients_NNS were_VBD tested_VBN for_IN the_DT presence_NN of_IN HPV_NP DNA_NP regardless_RB of_IN Pap_NN smear_NN status_NN ._SENT Demographic_JJ data_NNS were_VBD collected_VBN by_IN questionnaire_NN and_CC from_IN the_DT Adult_NP Spectrum_NP of_IN Disease_NP database_NN ._SENT Cervical_JJ swab_NN extractions_NNS ._SENT |_SYM One_CD cervical_JJ swab_NN specimen_NN was_VBD collected_VBN from_IN each_DT patient_NN by_IN use_NN of_IN a_DT Dacron_NP swab_NN ;_: the_DT swab_NN was_VBD then_RB placed_VBN in_IN 1_CD ml_NN of_IN Digene_NP transport_NN medium_NN and_CC stored_VBN at_IN 4C_JJ until_IN use_NN ._SENT Sample_NN extraction_NN was_VBD based_VBN on_IN the_DT protocol_NN by_IN Ting_NP and_CC Manos_NP ._SENT The_DT samples_NNS were_VBD digested_VBN at_IN 37C_JJ in_IN 50_CD mM_NP proteinase_NN K_NP digestion_NN solution_NN (_( Gibco_NP BRL_NP ,_, Gaithersburg_NP ,_, Md._NP )_) for_IN 1_CD to_TO 2_CD h._NNS The_DT DNA_NN was_VBD then_RB precipitated_VBN with_IN a_DT solution_NN of_IN 3_CD M_NP ammonium_NN acetate_NN in_IN 100_CD %_NN ethanol_NN at_IN twice_RB the_DT volume_NN of_IN the_DT original_JJ sample_NN ._SENT The_DT DNA_NP pellets_NNS were_VBD resuspended_VBN in_IN 50_CD mul_NN of_IN TE_JJ buffer_NN (_( 10_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.4_CD ]_SYM ,_, 1_CD mM_NP EDTA_NP [_SYM pH_NN 8.0_CD ]_SYM )_) and_CC stored_VBN at_IN -20C_NN until_IN use_NN ._SENT Extraction_NN of_IN DNA_NN from_IN urine_NN ._SENT |_SYM All_DT urine_NN specimens_NNS collected_VBN were_VBD stored_VBN at_IN -20C_NN for_IN a_DT minimum_NN of_IN 24_CD h._JJ Two_NP milliliters_NNS of_IN each_DT urine_NN sample_NN was_VBD then_RB concentrated_VBN in_IN an_DT Amicon_NP 100_CD protein_NN concentration_NN filter_NN (_( Millipore_NP Corporation_NP ,_, Bedford_NP ,_, Mass._NP )_) by_IN centrifugation_NN at_IN 2,087_CD x_NN g_NN for_IN 30_CD to_TO 45_CD min_NN at_IN room_NN temperature_NN ,_, according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT The_DT resulting_VBG filtrate_NN was_VBD then_RB resuspended_VBN in_IN 200_CD mul_NN of_IN 1x_NP phosphate-buffered_JJ saline_NN (_( 0.2_CD M_NP phosphate_NN ,_, 1.5_CD M_NP sodium_NN chloride_NN [_SYM pH_NN 7.4_CD ]_SYM )_) ,_, and_CC the_DT DNA_NN was_VBD extracted_VBN with_IN a_DT Qiagen_NP DNA_NP Mini_NP kit_NN (_( Qiagen_NP Inc._NP Valencia_NP ,_, Calif._NP )_) ._SENT These_DT DNA_NP extractions_NNS were_VBD performed_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS Blood_NP and_CC Body_NP Fluid_NP Spin_NP Protocol_NP and_CC were_VBD stored_VBN at_IN -20C_NN until_IN use_NN ._SENT PCR_NP ._SENT |_SYM Urine_NP and_CC matching_VBG cervical_JJ swab_NN specimens_NNS were_VBD subjected_VBN to_TO 40_CD cycles_NNS of_IN PCR_NP for_IN amplification_NN of_IN the_DT L1_JJ open_JJ reading_NN frame_NN of_IN HPV_NP by_IN using_VBG the_DT PGMY09-PGMY11_JJ consensus_NN primer_NN system_NN labeled_VBN with_IN biotin_NN (_( final_JJ concentration_NN ,_, 1_CD muM_NN )_) ._SENT The_DT biotin-labeled_JJ GH20-PC04_NP (_( beta-globin_NN )_) primer_NN system_NN (_( final_JJ concentration_NN ,_, 0.025_CD muM_NN )_) was_VBD also_RB included_VBN in_IN the_DT reaction_NN mixture_NN ._SENT MgCl2_NP was_VBD used_VBN at_IN a_DT concentration_NN of_IN 4_CD mM_NNS ,_, along_RB with_IN 1x_NP PCR_NP buffer_NN II_NP ,_, 1.5_CD U_NP of_IN AmpliTaq_NP Gold_NP DNA_NP polymerase_NN (_( Perkin_NP Elmer_NP )_) ,_, and_CC 1_CD muM_NN deoxynucleoside_NN triphosphates_NNS (_( Perkin-Elmer_NP )_) ._SENT The_DT DNA_NN types_NNS of_IN the_DT HPV_NP isolates_VBZ from_IN cervical_JJ swab_NN specimens_NNS and_CC the_DT matching_VBG urine_NN samples_NNS were_VBD determined_VBN by_IN using_VBG the_DT reverse_JJ line_NN hybridization_NN system_NN by_IN the_DT protocol_NN developed_VBN by_IN Gravitt_NP et_FW al._FW ._SENT All_DT reagents_NNS were_VBD provided_VBN by_IN Roche_NP Molecular_NP Systems_NP ,_, Alameda_NP ,_, Calif._NP Briefly_NP ,_, probes_NNS for_IN the_DT L1_JJ regions_NNS of_IN the_DT 27_CD HPV_NP genital_JJ types_NNS were_VBD conjugated_VBN to_TO a_DT long_JJ strip_NN of_IN nylon_NN membrane_NN with_IN bovine_JJ serum_NN albumin_NN ._SENT Biotinylated_JJ PCR_NP products_NNS were_VBD denatured_VBN by_IN adding_VBG EDTA_NP (_( 1.6_CD %_NN )_) ,_, sodium_NN hydroxide_NN (_( 0.13_CD N_NP )_) ,_, and_CC thymol_NN blue_JJ dye_NN for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT Next_RB ,_, the_DT samples_NNS were_VBD hybridized_VBN to_TO the_DT probes_NNS on_IN the_DT strips_NNS by_IN using_VBG hybridization_NN buffer_NN containing_VBG 4x_NP SSPE_NP (_( 1x_NP SSPE_NP is_VBZ 0.18_CD M_NP NaCl_NP ,_, 10_CD mM_NP NaH2PO4_NP ,_, and_CC 1_CD mM_NP EDTA_NP [_SYM pH_NN 7.4_CD ]_SYM )_) and_CC 0.1_CD %_NN sodium_NN dodecyl_NN sulfate_NN for_IN 30_CD min_NN at_IN 53C_NP ._SENT The_DT samples_NNS were_VBD washed_VBN once_RB with_IN 1x_NP SSPE-0.1_NP %_NN sodium_NN dodecyl_NN sulfate_NN at_IN 53C_NP and_CC were_VBD then_RB incubated_VBN for_IN 0.5_CD h_NN at_IN room_NN temperature_NN with_IN streptavidin-horseradish_JJ peroxidase_NN conjugate_JJ solution_NN ._SENT The_DT strips_NNS were_VBD then_RB washed_VBN twice_RB at_IN room_NN temperature_NN for_IN 10_CD min_NN ._SENT The_DT pH_NN of_IN the_DT samples_NNS was_VBD then_RB lowered_VBN by_IN the_DT brief_JJ addition_NN of_IN sodium_NN citrate_NN buffer_NN (_( 3_CD ml_NN ;_: 0.1_CD M_NN )_) ._SENT Lastly_RB ,_, a_DT developing_VBG solution_NN (_( 2_CD parts_NNS of_IN part_NN A_NP [_SYM a_DT citrate_NN solution_NN containing_VBG 0.01_CD %_NN H2O2_NP ]_SYM to_TO 1_CD part_NN of_IN part_NN B_NP [_SYM 0.1_CD %_NN 3,3',5,5'-tetramethylbenzidine_NN ]_SYM )_) was_VBD added_VBN ,_, and_CC the_DT strips_NNS were_VBD developed_VBN for_IN 5_CD to_TO 10_CD min_NN ._SENT Finally_RB ,_, sodium_NN citrate_NN buffer_NN (_( 3_CD ml_NN ;_: 0.1_CD M_NN )_) was_VBD added_VBN to_TO stop_VB the_DT reaction_NN ._SENT Data_NP analysis_NN ._SENT |_SYM Statistical_NP significance_NN was_VBD determined_VBN with_IN the_DT SPSS_NP program_NN (_( version_NN 9_CD ;_: SPSS_NP Inc._NP ,_, Chicago_NP ,_, Ill._NP )_) for_IN the_DT McNemar_NP test_NN ,_, the_DT Fisher_NP exact_JJ test_NN ,_, likelihood_NN ,_, and_CC odds_NNS ratios_NNS ._SENT The_DT Epi6_NP program_NN (_( Centers_NPS for_IN Disease_NP Control_NP and_CC Prevention_NP ,_, Atlanta_NP ,_, Ga._NP ,_, and_CC World_NP Health_NP Organization_NP ,_, Geneva_NP ,_, Switzerland_NP )_) was_VBD used_VBN to_TO determine_VB P_NN values_NNS generated_VBN from_IN proportion_NN tables_NNS ._SENT The_DT study_NN population_NN consisted_VBN of_IN 101_CD HIV-positive_JJ women_NNS recruited_VBN from_IN the_DT HIV_NP Outpatient_NP Clinic_NP in_IN New_NP Orleans_NP ,_, La._NP ,_, who_WP donated_VBD urine_NN specimens_NNS and_CC matching_VBG cervical_JJ swab_NN specimens_NNS ._SENT The_DT demographics_NNS of_IN patients_NNS from_IN the_DT HIV_NP Outpatient_NP Clinic_NP as_RB well_RB as_IN the_DT women_NNS in_IN the_DT urine_NN study_NN are_VBP presented_VBN in_IN Table_NP ._SENT There_EX were_VBD no_DT obvious_JJ differences_NNS in_IN the_DT characteristics_NNS of_IN the_DT urine_NN study_NN population_NN compared_VBN to_TO those_DT of_IN the_DT HIV_NP Outpatient_NP Clinic_NP population_NN except_IN that_WDT the_DT urine_NN study_NN contained_VBD a_DT significantly_RB higher_JJR percentage_NN of_IN women_NNS in_IN the_DT 30-_CD to_TO 39-year-old_JJ age_NN group_NN (_( P_NN =_SYM 0.05_CD )_) ._SENT The_DT ability_NN to_TO amplify_VB the_DT samples_NNS was_VBD determined_VBN by_IN visualization_NN of_IN the_DT beta-globin_NN housekeeping_NN gene_NN by_IN the_DT reverse_JJ line_NN hybridization_NN assay_NN ._SENT beta-globin_NP DNA_NP was_VBD amplifiable_JJ from_IN 87_CD %_NN of_IN the_DT cervical_JJ swab_NN specimens_NNS and_CC 73_CD %_NN of_IN the_DT urine_NN specimens_NNS (_( P_NN =_SYM 0.01_CD )_) ._SENT Thus_RB ,_, there_EX was_VBD a_DT significant_JJ difference_NN in_IN the_DT ability_NN to_TO amplify_VB DNA_NN from_IN urine_NN specimens_NNS compared_VBN to_TO the_DT ability_NN to_TO amplify_VB DNA_NN from_IN cervical_JJ swab_NN specimens_NNS ._SENT However_RB ,_, the_DT detection_NN of_IN any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, and_CC any_DT low-risk_JJ HPV_NP type_NN between_IN the_DT two_CD types_NNS of_IN samples_NNS was_VBD not_RB significantly_RB different_JJ for_IN this_DT population_NN (_( P_NN =_SYM 0.12_CD ,_, 0.26_CD ,_, and_CC 0.18_CD ,_, respectively_RB )_) ._SENT Interestingly_RB ,_, detection_NN of_IN HPV_NP between_IN the_DT two_CD sample_NN types_NNS was_VBD better_JJR when_WRB one_PP considered_VBD only_RB urine_NN samples_NNS (_( n_NN =_SYM 74_CD )_) from_IN which_WDT beta-globin_NN DNA_NN could_MD be_VB amplified_VBN or_CC only_RB cervical_JJ swab_NN specimens_NNS (_( n_NN =_SYM 88_CD )_) from_IN which_WDT beta-globin_NN DNA_NN could_MD be_VB amplified_VBN ._SENT In_IN this_DT analysis_NN ,_, 48_CD of_IN 74_CD (_( 65_CD %_NN )_) urine_NN samples_NNS and_CC 59_CD of_IN 88_CD (_( 67_CD %_NN )_) cervical_JJ swab_NN specimens_NNS contained_VBD any_DT HPV_NP type_NN (_( P_NN =_SYM 0.77_CD )_) ;_: 45_CD of_IN 74_CD (_( 61_CD %_NN )_) urine_NN samples_NNS from_IN which_WDT beta-globin_NN DNA_NN could_MD be_VB amplified_VBN contained_VBD any_DT high-risk_JJ HPV_NP DNA_NP type_NN ,_, while_IN 52_CD of_IN 88_CD (_( 59_CD %_NN )_) cervical_JJ swab_NN specimens_NNS from_IN which_WDT beta-globin_NN DNA_NN could_MD be_VB amplified_VBN contained_VBN high-risk_JJ HPV_NP DNA_NP types_NNS (_( P_NN =_SYM 0.82_CD )_) ._SENT Twenty_CD of_IN 74_CD (_( 27_CD %_NN )_) urine_NN samples_NNS from_IN which_WDT beta-globin_NN DNA_NN could_MD be_VB amplified_VBN were_VBD positive_JJ for_IN low-risk_JJ HPV_NP DNA_NN types_NNS ,_, whereas_IN 28_CD of_IN 88_CD (_( 32_CD %_NN )_) cervical_JJ swab_NN specimens_NNS were_VBD positive_JJ for_IN low-risk_JJ HPV_NP DNA_NP types_NNS (_( P_NN =_SYM 0.50_CD )_) (_( data_NNS not_RB shown_VBN )_) ._SENT Lastly_RB ,_, Fig._NN demonstrates_VBZ that_IN 27_CD of_IN 101_CD (_( 27_CD %_NN )_) urine_NN specimens_NNS and_CC 35_CD of_IN 101_CD (_( 35_CD %_NN )_) cervical_JJ swab_NN specimens_NNS were_VBD infected_VBN with_IN more_JJR than_IN one_CD HPV_NP type_NN and_CC 21_CD of_IN 101_CD (_( 21_CD %_NN )_) urine_NN specimens_NNS and_CC 26_CD of_IN 101_CD (_( 26_CD %_NN )_) cervical_JJ swab_NN specimens_NNS were_VBD infected_VBN with_IN more_JJR than_IN one_CD of_IN any_DT of_IN the_DT high-risk_JJ HPV_NP DNA_NN types_NNS ._SENT Of_IN the_DT samples_NNS infected_VBN with_IN multiple_JJ HPV_NP DNA_NN types_NNS ,_, the_DT average_JJ number_NN of_IN low-risk_JJ and_CC high-risk_JJ HPV_NP types_NNS detected_VBD in_IN each_DT sample_NN were_VBD 3.4_CD (_( range_NN ,_, 2_CD to_TO 4_CD )_) and_CC 3.2_CD (_( range_NN ,_, 2_CD to_TO 6_CD )_) ,_, respectively_RB ,_, for_IN the_DT urine_NN specimens_NNS and_CC 4.1_CD (_( range_NN ,_, 2_CD to_TO 4_CD )_) and_CC 3.1_CD (_( range_NN ,_, 2_CD to_TO 8_CD )_) ,_, respectively_RB ,_, for_IN the_DT cervical_JJ swab_NN specimens_NNS ._SENT The_DT reverse_JJ line_NN hybridization_NN assay_NN detects_VBZ 27_CD different_JJ types_NNS of_IN HPV_NP (_( 18_CD high-risk_JJ types_NNS and_CC 9_CD low-risk_JJ types_NNS )_) ._SENT None_NN of_IN the_DT HPV_NP DNA_NP detected_VBD in_IN this_DT study_NN was_VBD nontypeable_JJ (_( agarose_JJ gel_NN electrophoresis_NN positive_JJ ,_, reverse_JJ line_NN hybridization_NN assay_NN negative_JJ )_) ._SENT When_WRB the_DT overall_JJ distribution_NN of_IN HPV_NP types_NNS detected_VBD in_IN the_DT urine_NN specimens_NNS was_VBD compared_VBN with_IN the_DT overall_JJ distribution_NN of_IN HPV_NP types_NNS detected_VBD in_IN the_DT cervical_JJ swab_NN specimens_NNS ,_, virtually_RB no_DT differences_NNS were_VBD observed_VBN for_IN 21_CD of_IN the_DT 27_CD types_NNS represented_VBD ._SENT For_IN types_NNS 53_CD ,_, MM4_NP ,_, MM7_JJ ,_, 54_CD ,_, and_CC 55_CD ,_, discordance_NN was_VBD detected_VBN more_RBR frequently_RB for_IN the_DT cervical_JJ swab_NN specimens_NNS (_( incidence_NN in_IN cervical_JJ swab_NN specimens_NNS versus_CC incidence_NN in_IN urine_NN specimens_NNS ,_, >2.0_JJ )_) ._SENT For_IN type_NN MM9_NP ,_, discordance_NN was_VBD detected_VBN more_RBR frequently_RB for_IN the_DT urine_NN specimens_NNS (_( incidence_NN in_IN urine_NN specimens_NNS versus_CC incidence_NN in_IN cervical_JJ swab_NN specimens_NNS ,_, >2.0_JJ )_) ._SENT However_RB ,_, these_DT comparisons_NNS were_VBD not_RB statistically_RB significantly_RB different_JJ (_( P_NN >=_NN 0.11_CD for_IN all_DT comparisons_NNS )_) ._SENT It_PP is_VBZ possible_JJ that_IN the_DT relative_JJ insensitivity_NN of_IN the_DT assay_NN with_IN urine_NN for_IN the_DT detection_NN of_IN cervical_JJ HPV_NP types_NNS 53_CD ,_, MM4_NP ,_, MM7_JJ ,_, 54_CD ,_, and_CC 55_CD may_MD become_VB a_DT potential_JJ limitation_NN of_IN the_DT assay_NN ._SENT Concordance_NN is_VBZ a_DT measure_NN of_IN whether_IN both_DT samples_NNS had_VBD any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, or_CC any_DT low-risk_JJ HPV_NP type_NN or_CC whether_IN no_DT HPV_NP was_VBD present_JJ in_IN the_DT paired_VBN samples_NNS ._SENT The_DT rates_NNS of_IN concordance_NN were_VBD 70_CD %_NN for_IN any_DT HPV_NP type_NN ,_, 71_CD %_NN for_IN any_DT high-risk_JJ HPV_NP type_NN ,_, and_CC 78_CD %_NN for_IN any_DT low-risk_JJ HPV_NP type_NN ._SENT The_DT rates_NNS at_IN which_WDT HPV_NP occurred_VBD more_RBR frequently_RB in_IN the_DT cervix_NN than_IN in_IN the_DT urine_NN are_VBP as_RB follows_VBZ for_IN any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, or_CC any_DT low-risk_JJ HPV_NP type_NN :_: 21_CD versus_IN 9_CD %_NN (_( P_NN =_SYM 0.04_CD )_) ,_, 19_CD versus_CC 11_CD %_NN (_( P_NN =_SYM 0.20_CD )_) ,_, and_CC 15_CD versus_CC 7_CD %_NN (_( P_NN =_SYM 0.13_CD )_) ,_, respectively_RB (_( data_NNS not_RB shown_VBN )_) ._SENT Although_IN the_DT test_NN with_IN urine_NN specimens_NNS detected_VBD fewer_JJR instances_NNS of_IN discordance_NN for_IN any_DT HPV_NP type_NN ,_, it_PP was_VBD not_RB statistically_RB significantly_RB different_JJ from_IN the_DT instances_NNS of_IN discordant_JJ results_NNS for_IN cervical_JJ swab_NN specimens_NNS for_IN the_DT detection_NN of_IN any_DT high-_NN or_CC low-risk_JJ HPV_NP type_NN in_IN this_DT analysis_NN ._SENT Table_NN illustrates_VBZ the_DT risk_NN of_IN detection_NN of_IN HPV_NP DNA_NP in_IN urine_NN and_CC the_DT cervix_NN in_IN association_NN with_IN an_DT abnormal_JJ Pap_NN smear_NN ._SENT Of_IN the_DT 97_CD patients_NNS in_IN the_DT study_NN for_IN whom_WP Pap_NN smear_NN data_NNS were_VBD available_JJ ,_, 53_CD had_VBD Pap_NN smears_NNS within_IN normal_JJ limits_NNS (_( WNL_NP )_) ,_, 17_CD had_VBD Pap_NN smear_NN results_NNS indicating_VBG ASCUS_NP ,_, and_CC 27_CD patients_NNS had_VBD Pap_NN smears_NNS graded_VBD low-grade_NN squamous_JJ intraepithelial_JJ lesion_NN (_( LGSIL_NP )_) or_CC high-grade_JJ squamous_JJ intraepithelial_JJ lesion_NN (_( HGSIL_NP )_) ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS between_IN urine_NN and_CC the_DT cervix_NN in_IN terms_NNS of_IN the_DT percentage_NN of_IN any_DT HPV_NP type_NN or_CC a_DT high-risk_JJ HPV_NP type_NN of_IN the_DT different_JJ cytologic_JJ grades_NNS detected_VBD ._SENT Figure_NN also_RB illustrates_VBZ that_IN for_IN women_NNS with_IN normal_JJ Pap_NN smears_NNS ,_, the_DT rate_NN of_IN detection_NN of_IN any_DT HPV_NP type_NN was_VBD 15_CD %_NN higher_JJR in_IN the_DT cervix_NN than_IN in_IN urine_NN ._SENT The_DT ages_NNS ,_, races_NNS ,_, CD4_NP T-cell_NN counts_NNS ,_, and_CC HIV_NP loads_NNS of_IN the_DT patients_NNS included_VBD in_IN the_DT urine_NN study_NN were_VBD examined_VBN and_CC were_VBD found_VBN by_IN multivariate_JJ analysis_NN not_RB to_TO be_VB independent_JJ risk_NN factors_NNS for_IN having_VBG either_RB an_DT abnormal_JJ Pap_NN smear_NN or_CC an_DT abnormal_JJ Pap_NN smear_NN including_VBG ASCUS_NP ._SENT When_WRB these_DT factors_NNS were_VBD adjusted_VBN for_IN ,_, the_DT detection_NN of_IN any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, multiple_JJ HPV_NP types_NNS ,_, or_CC multiple_JJ high-risk_JJ HPV_NP types_NNS was_VBD significantly_RB associated_VBN with_IN having_VBG an_DT abnormal_JJ Pap_NN smear_NN or_CC an_DT abnormal_JJ Pap_NN smear_NN including_VBG ASCUS_NP for_IN both_DT urine_NN and_CC cervical_JJ swab_NN specimens_NNS ._SENT Incidentally_RB ,_, neither_CC HPV_NP DNA_NP nor_CC beta-globin_NP DNA_NP could_MD be_VB amplified_VBN from_IN 27_CD urine_NN specimens_NNS and_CC 13_CD cervical_JJ swab_NN specimens_NNS ._SENT The_DT Pap_NN smear_NN results_NNS for_IN these_DT patients_NNS were_VBD as_RB follows_VBZ :_: for_IN urine_NN specimens_NNS ,_, 3_CD of_IN 27_CD (_( 11_CD %_NN )_) patients_NNS did_VBD not_RB have_VB Pap_NN smear_NN data_NNS available_JJ ,_, 16_CD of_IN 27_CD (_( 59_CD %_NN )_) patients_NNS had_VBD WNL_NP ,_, 4_CD of_IN 27_CD (_( 15_CD %_NN )_) patients_NNS had_VBD ASCUS_NP ,_, and_CC 4_CD of_IN 27_CD (_( 15_CD %_NN )_) patients_NNS had_VBD LGSIL_NP ;_: for_IN the_DT cervical_JJ swab_NN specimens_NNS ,_, 6_CD of_IN 13_CD (_( 46_CD %_NN )_) patients_NNS had_VBD WNL_NP ,_, 3_CD of_IN 13_CD (_( 23_CD %_NN )_) patients_NNS had_VBD ASCUS_NP ,_, 3_CD of_IN 13_CD (_( 23_CD %_NN )_) patients_NNS had_VBD LGSIL_NP ,_, and_CC 1_CD of_IN 13_CD (_( 7_CD %_NN )_) patients_NNS had_VBD HGSIL_NP ._SENT There_EX was_VBD no_DT further_JJR investigation_NN as_IN to_TO why_WRB neither_DT HPV_NP DNA_NP nor_CC beta-globin_NP DNA_NP could_MD be_VB amplified_VBN from_IN these_DT samples_NNS by_IN the_DT PCR_NP assay_NN in_IN this_DT study_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Prevalence_NN of_IN any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, any_DT low-risk_JJ HPV_NP DNA_NP type_NN ,_, or_CC the_DT presence_NN of_IN a_DT multiple_JJ infection_NN in_IN urine_NN or_CC cervix_NN for_IN entire_JJ study_NN population_NN of_IN 101_CD HIV-positive_JJ women_NNS ._SENT Prevalence_NN of_IN any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, any_DT low-risk_JJ HPV_NP DNA_NP type_NN ,_, or_CC the_DT presence_NN of_IN a_DT multiple_JJ infection_NN in_IN urine_NN or_CC cervix_NN for_IN entire_JJ study_NN population_NN of_IN 101_CD HIV-positive_JJ women_NNS ._SENT The_DT amplifiability_NN of_IN HPV_NP DNA_NP from_IN urine_NN and_CC cervical_JJ swab_NN specimens_NNS is_VBZ also_RB compared_VBN in_IN the_DT first_JJ column_NN ._SENT White_JJ bars_NNS ,_, urine_NN samples_NNS ;_: thatched_VBN bars_NNS ,_, cervical_JJ swab_NN samples_NNS ._SENT Significant_JJ differences_NNS are_VBP denoted_VBN by_IN an_DT asterisk_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT FIG._NN 2_CD ._SENT |_SYM Detection_NN of_IN any_DT HPV_NP DNA_NP type_NN or_CC any_DT high-risk_JJ HPV_NP DNA_NN type_NN in_IN urine_NN and_CC cervix_NN of_IN women_NNS with_IN normal_JJ Pap_NN smears_NNS (_( WNL_NP ;_: n_NN =_SYM 53_CD )_) ,_, ASCUS_NP (_( n_NN =_SYM 17_CD )_) ,_, or_CC abnormal_JJ Pap_NN smears_NNS (_( n_NN =_SYM 27_CD )_) ._SENT Detection_NN of_IN any_DT HPV_NP DNA_NP type_NN or_CC any_DT high-risk_JJ HPV_NP DNA_NN type_NN in_IN urine_NN and_CC cervix_NN of_IN women_NNS with_IN normal_JJ Pap_NN smears_NNS (_( WNL_NP ;_: n_NN =_SYM 53_CD )_) ,_, ASCUS_NP (_( n_NN =_SYM 17_CD )_) ,_, or_CC abnormal_JJ Pap_NN smears_NNS (_( n_NN =_SYM 27_CD )_) ._SENT White_JJ bars_NNS ,_, any_DT HPV_NP DNA_NN type_NN in_IN urine_NN ;_: bars_NNS with_IN vertical_JJ stripes_NNS ,_, any_DT HPV_NP DNA_NN type_NN in_IN the_DT cervix_NN ;_: bars_NNS with_IN horizontal_JJ stripes_NNS ,_, any_DT high-risk_JJ HPV_NP DNA_NN type_NN in_IN urine_NN ;_: bars_NNS with_IN angled_VBN thatching_VBG ,_, any_DT high-risk_JJ HPV_NP DNA_NN type_NN in_IN the_DT cervix_NN ._SENT The_DT percentage_NN of_IN urine_NN or_CC cervical_JJ swab_NN samples_NNS positive_JJ for_IN HPV_NP DNA_NP is_VBZ indicated_VBN above_IN each_DT bar_NN for_IN each_DT Pap_NN smear_NN classification_NN ._SENT TABLE_NN 1_CD |_SYM Demographic_JJ and_CC clinical_JJ characteristics_NNS of_IN current_JJ HIV_NP Outpatient_NP Clinic_NP female_JJ population_NN and_CC urine_NN study_NN participants_NNS TABLE_NP 2_CD |_SYM Distribution_NN of_IN high-_NN and_CC low-risk_JJ HPV_NP types_NNS in_IN urine_NN and_CC cervix_NN of_IN HIV-positive_JJ women_NNS infected_VBN with_IN single_JJ and_CC multiple_JJ HPV_NP types_NNS TABLE_NP 3_CD |_SYM Association_NN of_IN Pap_NN smear_NN status_NN with_IN detection_NN of_IN HPV_NP in_IN urine_NN and_CC cervix_NN The_DT validity_NN of_IN a_DT PCR_NP utilizing_VBG urine_NN for_IN the_DT detection_NN of_IN HPV_NP DNA_NP was_VBD examined_VBN in_IN these_DT studies_NNS ._SENT The_DT beta-globin_NN housekeeping_NN gene_NN was_VBD amplified_VBN from_IN 87_CD %_NN of_IN the_DT cervical_JJ swab_NN specimens_NNS but_CC only_RB 73_CD %_NN of_IN the_DT urine_NN specimens_NNS ._SENT This_DT demonstrates_VBZ that_IN despite_IN our_PP$ best_JJS efforts_NNS ,_, the_DT rate_NN of_IN amplifiability_NN of_IN HPV_NP DNA_NP from_IN a_DT cervical_JJ swab_NN specimen_NN is_VBZ significantly_RB higher_JJR than_IN that_DT from_IN a_DT urine_NN specimen_NN ._SENT This_DT could_MD simply_RB be_VB due_JJ to_TO the_DT fact_NN that_IN urine_NN samples_NNS from_IN healthy_JJ women_NNS contain_VBP relatively_RB few_JJ cells_NNS [_SYM Microscopic_JJ examination_NN of_IN sediment_NN ,_, p._NN 78_CD ,_, H._NP M._NP Free_NP (_( ed_NN ._SENT )_) ,_, Modern_NP urine_NN chemistry_NN ,_, Bayer_NP Diagnostics_NP Division_NP ,_, Bayer_NP Corporation_NP ,_, Tarrytown_NP ,_, N.Y._NP ,_, 1996_CD ]_SYM or_CC that_DT urine_NN contains_VBZ inhibitors_NNS of_IN the_DT PCR_NP ._SENT The_DT rates_NNS of_IN detection_NN of_IN any_DT HPV_NP DNA_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, and_CC any_DT low-risk_JJ HPV_NP type_NN were_VBD not_RB statistically_RB different_JJ between_IN the_DT urine_NN specimens_NNS and_CC the_DT cervical_JJ swab_NN specimens_NNS for_IN this_DT population_NN ._SENT This_DT may_MD imply_VB that_IN a_DT patient_NN whose_WP$ cervix_NN is_VBZ infected_VBN with_IN HPV_NP is_VBZ more_RBR likely_JJ to_TO shed_VB HPV-infected_JJ cervical_JJ cells_NNS that_WDT can_MD then_RB be_VB detected_VBN in_IN the_DT urine_NN of_IN that_DT patient_NN ._SENT This_DT possibility_NN is_VBZ not_RB particularly_RB surprising_JJ when_WRB one_PP considers_VBZ other_JJ virus_NN infection_NN systems_NNS ,_, like_IN the_DT cytomegalovirus_NN infection_NN system_NN ,_, in_IN which_WDT virus_NN is_VBZ often_RB shed_VBN in_IN the_DT urine_NN ._SENT Conversely_RB ,_, the_DT fact_NN that_IN significant_JJ differences_NNS in_IN rates_NNS of_IN HPV_NP DNA_NP detection_NN between_IN the_DT urine_NN and_CC the_DT cervix_NN were_VBD not_RB detected_VBN in_IN the_DT present_JJ cohort_NN may_MD simply_RB be_VB due_JJ to_TO a_DT lack_NN of_IN power_NN due_JJ to_TO the_DT size_NN of_IN the_DT population_NN studied_VBD ._SENT Future_JJ studies_NNS with_IN increased_VBN numbers_NNS of_IN paired_VBN samples_NNS are_VBP needed_VBN in_IN order_NN to_TO strengthen_VB these_DT observations_NNS ._SENT The_DT overall_JJ prevalence_NN of_IN detection_NN of_IN any_DT HPV_NP DNA_NP was_VBD 48_CD %_NN for_IN the_DT urine_NN specimens_NNS and_CC 58_CD %_NN for_IN the_DT cervical_JJ swab_NN specimens_NNS ._SENT These_DT rates_NNS are_VBP higher_JJR than_IN those_DT found_VBN in_IN other_JJ recent_JJ studies_NNS ._SENT One_CD study_NN conducted_VBN by_IN Strauss_NP et_FW al._FW with_IN 144_CD women_NNS attending_VBG a_DT genitourinary_JJ clinic_NN demonstrated_VBN HPV_NP DNA_NP in_IN 40_CD %_NN of_IN cervical_JJ swab_NN samples_NNS and_CC 15_CD %_NN of_IN urine_NN specimens_NNS by_IN first-round_NP PCR_NP amplification_NN ._SENT Another_DT study_NN conducted_VBN with_IN 489_CD patients_NNS who_WP were_VBD referred_VBN to_TO a_DT colposcopy_NN clinic_NN detected_VBD HPV_NP DNA_NP in_IN 49_CD %_NN of_IN the_DT cervical_JJ swab_NN specimens_NNS and_CC 38_CD %_NN of_IN the_DT urine_NN specimens_NNS ._SENT The_DT differences_NNS in_IN prevalence_NN between_IN these_DT studies_NNS and_CC the_DT present_JJ study_NN may_MD simply_RB be_VB due_JJ to_TO the_DT different_JJ populations_NNS that_WDT were_VBD evaluated_VBN ._SENT Because_IN of_IN the_DT sexually_RB acquired_VBN nature_NN of_IN their_PP$ disease_NN ,_, HIV-positive_JJ women_NNS probably_RB experience_VBP increased_VBN levels_NNS of_IN exposure_NN to_TO HPV_NP as_RB well_RB as_IN other_JJ STDs_NNS ._SENT This_DT would_MD result_VB in_IN a_DT higher_JJR overall_JJ prevalence_NN of_IN HPV_NP infection_NN in_IN this_DT population_NN ._SENT The_DT prevalence_NN rates_NNS found_VBN in_IN the_DT present_JJ study_NN also_RB differ_VBP from_IN those_DT found_VBN in_IN a_DT recent_JJ study_NN conducted_VBN by_IN Sellors_NP et_FW al._FW with_IN a_DT population_NN of_IN women_NNS who_WP were_VBD attending_VBG a_DT colposcopy_NN clinic_NN ._SENT The_DT overall_JJ prevalence_NN of_IN HPV_NP of_IN any_DT type_NN in_IN the_DT study_NN by_IN Sellors_NP et_FW al._FW was_VBD 35_CD %_NN in_IN urine_NN specimens_NNS and_CC 63_CD %_NN in_IN physician-obtained_JJ cervical_JJ swab_NN specimens_NNS ._SENT The_DT discrepancy_NN between_IN the_DT two_CD studies_NNS can_MD again_RB be_VB explained_VBN in_IN part_NN by_IN the_DT different_JJ populations_NNS examined_VBD ._SENT The_DT study_NN of_IN women_NNS attending_VBG a_DT colposcopy_NN clinic_NN contained_VBD only_JJ women_NNS who_WP had_VBD an_DT abnormal_JJ Pap_NN smear_NN (_( ASCUS_NP ,_, LGSIL_NP ,_, HGSIL_NP ,_, or_CC adenocarcinoma_NN )_) ._SENT Conversely_RB ,_, 52.5_CD %_NN of_IN the_DT HIV-positive_JJ population_NN evaluated_VBN in_IN the_DT present_JJ study_NN had_VBD Pap_NN smear_NN gradings_NNS within_IN normal_JJ limits_NNS ,_, which_WDT would_MD lead_VB to_TO overall_RB lower_JJR prevalence_NN rates_NNS in_IN cervical_JJ swab_NN samples_NNS ._SENT Additionally_RB ,_, the_DT higher_JJR prevalence_NN seen_VBN in_IN the_DT urine_NN specimens_NNS in_IN the_DT urine_NN study_NN with_IN HIV-positive_JJ women_NNS may_MD simply_RB reflect_VB differences_NNS in_IN specimen_NN handling_NN and_CC extraction_NN techniques_NNS between_IN the_DT two_CD studies_NNS ._SENT Lastly_RB ,_, the_DT prevalence_NN of_IN HPV_NP DNA_NP in_IN the_DT present_JJ study_NN was_VBD lower_JJR than_IN that_DT found_VBN in_IN another_DT recent_JJ study_NN conducted_VBN by_IN Jacobson_NP et_FW al._FW ._SENT They_PP detected_VBD HPV_NP DNA_NP at_IN relatively_RB high_JJ rates_NNS in_IN urine_NN (_( 75_CD %_NN )_) and_CC cervical_JJ swab_NN (_( 90_CD %_NN )_) specimens_NNS from_IN an_DT inner-city_JJ adolescent_JJ population_NN ._SENT Interestingly_RB ,_, although_IN no_DT patients_NNS under_IN 20_CD years_NNS of_IN age_NN were_VBD included_VBN in_IN the_DT present_JJ study_NN with_IN HIV-infected_JJ subjects_NNS ,_, the_DT rate_NN of_IN detection_NN of_IN any_DT HPV_NP type_NN in_IN urine_NN was_VBD highest_RBS (_( 79_CD %_NN )_) for_IN women_NNS ages_VBZ 20_CD to_TO 30_CD years_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Examination_NN of_IN the_DT samples_NNS for_IN the_DT 27_CD different_JJ HPV_NP types_NNS that_WDT are_VBP detected_VBN by_IN the_DT reverse_JJ line_NN hybridization_NN assay_NN revealed_VBD the_DT presence_NN of_IN 26_CD of_IN these_DT types_NNS in_IN the_DT patients_NNS in_IN the_DT urine_NN study_NN ._SENT The_DT diversity_NN of_IN HPV_NP types_NNS represented_VBD in_IN this_DT study_NN is_VBZ most_RBS likely_JJ a_DT reflection_NN of_IN the_DT high-risk_JJ behaviors_NNS of_IN these_DT women_NNS ._SENT When_WRB the_DT overall_JJ distribution_NN of_IN HPV_NP types_NNS that_WDT were_VBD detected_VBN in_IN the_DT urine_NN samples_NNS was_VBD compared_VBN with_IN the_DT overall_JJ distribution_NN of_IN HPV_NP types_NNS that_WDT were_VBD detected_VBN in_IN the_DT cervical_JJ swab_NN samples_NNS ,_, potential_JJ preferences_NNS for_IN the_DT detection_NN of_IN types_NNS 53_CD ,_, MM4_NP ,_, MM7_JJ ,_, 54_CD ,_, and_CC 55_CD were_VBD seen_VBN for_IN the_DT cervical_JJ swab_NN specimens_NNS and_CC a_DT potential_JJ preference_NN for_IN the_DT detection_NN of_IN type_NN MM9_NP was_VBD seen_VBN for_IN the_DT urine_NN samples_NNS ._SENT These_DT differences_NNS did_VBD not_RB reach_VB statistical_JJ significance_NN due_JJ to_TO the_DT small_JJ sample_NN sizes_NNS ._SENT HPV_NP type_NN MM9_NP is_VBZ considered_VBN to_TO be_VB of_IN intermediate_JJ to_TO high_JJ risk_NN as_IN a_DT cause_NN of_IN cervical_JJ cancer_NN ._SENT Type_NN MM9_NP may_MD represent_VB a_DT viral_JJ type_NN that_WDT is_VBZ tropic_JJ for_IN the_DT vagina_NN or_CC that_WDT primarily_RB infects_VBZ the_DT urethra_NN ._SENT Types_NNS 53_CD and_CC 54_CD are_VBP considered_VBN low_JJ risk_NN ;_: and_CC types_NNS 55_CD ,_, MM4_NP ,_, and_CC MM7_JJ are_VBP thought_VBN to_TO be_VB of_IN intermediate_JJ or_CC high_JJ risk_NN as_IN causes_NNS of_IN cervical_JJ cancer_NN ._SENT Perhaps_RB infections_NNS caused_VBN by_IN these_DT viral_JJ types_NNS are_VBP more_RBR likely_JJ to_TO be_VB localized_VBN only_RB to_TO the_DT cervix_NN or_CC have_VBP very_RB low_JJ copy_NN numbers_NNS so_RB that_IN the_DT virus_NN is_VBZ not_RB shed_VBN in_IN the_DT urine_NN ._SENT This_DT lack_NN of_IN sensitivity_NN for_IN these_DT types_NNS could_MD prove_VB to_TO be_VB a_DT limitation_NN of_IN urine_NN testing_NN ,_, which_WDT could_MD potentially_RB be_VB compensated_VBN for_IN by_IN taking_VBG multiple_JJ urine_NN specimens_NNS from_IN the_DT same_JJ patient_NN ._SENT Future_JJ studies_NNS are_VBP needed_VBN not_RB only_RB to_TO increase_VB the_DT sample_NN size_NN but_CC also_RB to_TO compare_VB the_DT site(s)_NN of_IN anogenital_JJ HPV_NP infection_NN in_IN women_NNS whose_WP$ urine_NN is_VBZ positive_JJ for_IN HPV_NP DNA_NP ._SENT Finally_RB ,_, HPV_NP type_NN 16_CD was_VBD commonly_RB found_VBN in_IN both_CC the_DT cervix_NN and_CC urine_NN ,_, as_RB seen_VBN previously_RB ._SENT However_RB ,_, the_DT other_JJ most_RBS common_JJ types_NNS found_VBN in_IN the_DT present_JJ study_NN (_( types_NNS 35_CD and_CC MM7_JJ in_IN the_DT cervix_NN and_CC type_NN 59_CD in_IN urine_NN )_) were_VBD either_RB not_RB tested_VBN for_IN or_CC found_VBD less_JJR often_RB in_IN the_DT inner-city_JJ adolescent_JJ population_NN ._SENT This_DT most_RBS likely_JJ reflects_VBZ the_DT differences_NNS in_IN the_DT populations_NNS tested_VBN between_IN the_DT two_CD studies_NNS ._SENT When_WRB the_DT rates_NNS of_IN concordance_NN of_IN the_DT results_NNS between_IN the_DT samples_NNS was_VBD compared_VBN ,_, the_DT results_NNS of_IN the_DT test_NN with_IN urine_NN were_VBD not_RB statistically_RB different_JJ from_IN those_DT of_IN tests_NNS with_IN cervical_JJ swabs_NNS for_IN the_DT detection_NN of_IN any_DT high-risk_JJ or_CC low-risk_JJ HPV_NP types_NNS for_IN specimen_NN pairs_NNS with_IN discordant_JJ results_NNS ._SENT However_RB ,_, when_WRB the_DT detection_NN of_IN any_DT HPV_NP type_NN is_VBZ considered_VBN ,_, HPV_NP DNA_NP of_IN any_DT type_NN was_VBD detected_VBN significantly_RB more_RBR frequently_RB in_IN the_DT cervical_JJ swab_NN specimens_NNS ._SENT This_DT is_VBZ most_RBS likely_RB due_JJ to_TO the_DT increased_VBN number_NN of_IN comparisons_NNS for_IN this_DT group_NN and_CC indicates_VBZ that_IN the_DT assay_NN with_IN urine_NN specimens_NNS may_MD be_VB a_DT slightly_RB less_RBR sensitive_JJ method_NN for_IN detecting_VBG HPV_NP DNA_NP than_IN the_DT assay_NN with_IN cervical_JJ swab_NN specimens_NNS ._SENT This_DT finding_NN may_MD also_RB be_VB a_DT reflection_NN of_IN the_DT natural_JJ history_NN of_IN HPV_NP infection_NN ,_, which_WDT may_MD be_VB detected_VBN more_RBR readily_RB in_IN urine_NN as_IN a_DT function_NN of_IN the_DT higher_JJR viral_JJ loads_NNS and_CC increased_VBD shedding_VBG of_IN infected_JJ cells_NNS ._SENT Determination_NN of_IN the_DT local_JJ HPV_NP load_NN would_MD help_VB prove_VB this_DT theory_NN ._SENT The_DT inability_NN to_TO detect_VB low-risk_JJ HPV_NP types_NNS in_IN urine_NN is_VBZ not_RB believed_VBN to_TO be_VB a_DT serious_JJ limitation_NN of_IN this_DT assay_NN ._SENT Table_NN examined_VBD the_DT risk_NN associated_VBN with_IN having_VBG an_DT abnormal_JJ Pap_NN smear_NN when_WRB HPV_NP DNA_NP was_VBD detected_VBN in_IN urine_NN or_CC cervical_JJ swab_NN samples_NNS ._SENT For_IN both_DT sample_NN types_NNS ,_, there_EX were_VBD significant_JJ associations_NNS between_IN having_VBG an_DT abnormal_JJ Pap_NN smear_NN or_CC an_DT abnormal_JJ Pap_NN smear_NN result_NN including_VBG ASCUS_NP and_CC detection_NN of_IN any_DT HPV_NP type_NN ,_, any_DT high-risk_JJ HPV_NP type_NN ,_, multiple_JJ HPV_NP types_NNS ,_, or_CC multiple_JJ high-risk_JJ HPV_NP types_NNS ._SENT Importantly_RB ,_, for_IN these_DT categories_NNS the_DT percentage_NN of_IN samples_NNS in_IN which_WDT HPV_NP DNA_NP was_VBD detected_VBN did_VBD not_RB differ_VB significantly_RB between_IN the_DT urine_NN specimens_NNS and_CC the_DT cervical_JJ swab_NN specimens_NNS (_( Fig._NN and_CC data_NNS not_RB shown_VBN )_) ._SENT These_DT data_NNS suggest_VBP that_IN testing_VBG of_IN urine_NN may_MD be_VB comparable_JJ to_TO testing_VBG of_IN a_DT cervical_JJ swab_NN specimen_NN for_IN HPV_NP DNA_NP detection_NN and_CC that_IN ,_, like_IN the_DT cervical_JJ swab_NN specimen_NN ,_, the_DT rate_NN of_IN HPV_NP DNA_NP detection_NN increases_NNS with_IN the_DT severity_NN of_IN the_DT abnormal_JJ Pap_NN smear_NN or_CC the_DT presence_NN of_IN HPV_NP disease_NN ._SENT These_DT data_NNS corroborate_VBP the_DT findings_NNS of_IN Vossler_NP et_FW al._FW ,_, who_WP demonstrated_VBD HPV_NP DNA_NP in_IN urine_NN specimens_NNS from_IN 13_CD of_IN 15_CD women_NNS who_WP had_VBD evidence_NN of_IN condylomata_NNS ,_, dysplasia_NN ,_, or_CC invasive_JJ carcinoma_NN but_CC in_IN only_RB 3_CD of_IN 6_CD women_NNS who_WP had_VBD normal_JJ Pap_NN smears_NNS ._SENT A_DT potential_JJ limitation_NN of_IN this_DT analysis_NN is_VBZ that_IN our_PP$ study_NN lacks_VBZ biopsy_NN data_NNS to_TO verify_VB the_DT findings_NNS of_IN an_DT abnormal_JJ Pap_NN smear_NN ._SENT Such_JJ data_NNS could_MD be_VB important_JJ for_IN determination_NN of_IN the_DT true_JJ positives_NNS in_IN the_DT group_NN with_IN abnormal_JJ Pap_NN smears_NNS ._SENT Unfortunately_RB ,_, an_DT ASCUS_NP or_CC even_RB a_DT low-grade_NN abnormal_JJ Pap_NN smear_NN is_VBZ not_RB always_RB cause_VB for_IN an_DT immediate_JJ biopsy_NN in_IN this_DT HIV-positive_JJ population_NN ,_, and_CC women_NNS with_IN normal_JJ smears_NNS are_VBP not_RB normally_RB subject_JJ to_TO a_DT biopsy_NN procedure_NN ._SENT Thus_RB ,_, with_IN so_RB few_JJ biopsy_NN data_NNS available_JJ for_IN this_DT study_NN ,_, Pap_NN smear_NN status_NN was_VBD used_VBN to_TO stratify_VB the_DT population_NN ._SENT Interestingly_RB ,_, in_IN women_NNS with_IN normal_JJ Pap_NN smears_VBZ the_DT rate_NN of_IN detection_NN of_IN any_DT HPV_NP type_NN was_VBD approximately_RB 15_CD %_NN greater_JJR in_IN the_DT cervix_NN than_IN in_IN urine_NN ._SENT In_IN the_DT present_JJ study_NN ,_, this_DT finding_NN was_VBD not_RB significant_JJ ._SENT However_RB ,_, it_PP be_VB will_NN interesting_JJ to_TO monitor_VB this_DT observation_NN in_IN future_JJ studies_NNS in_IN order_NN to_TO determine_VB if_IN screening_NN by_IN use_NN of_IN a_DT cervical_JJ swab_NN specimen_NN compared_VBN to_TO screening_VBG by_IN use_NN of_IN a_DT urine_NN sample_NN would_MD produce_VB a_DT higher_JJR percentage_NN of_IN false-positive_JJ results_NNS ._SENT In_IN summary_NN ,_, we_PP have_VBP developed_VBN a_DT urine-based_JJ assay_NN for_IN detection_NN of_IN the_DT DNA_NN of_IN HPV_NP ,_, which_WDT is_VBZ responsible_JJ for_IN nearly_RB all_DT cases_NNS of_IN cervical_JJ cancer_NN and_CC which_WDT is_VBZ of_IN particular_JJ concern_NN in_IN the_DT HIV-positive_JJ population_NN ._SENT The_DT assay_NN with_IN urine_NN appears_VBZ to_TO be_VB as_RB adept_JJ as_IN the_DT assay_NN with_IN a_DT cervical_JJ swab_NN specimen_NN for_IN the_DT detection_NN of_IN any_DT HPV_NP type_NN or_CC any_DT high-risk_JJ HPV_NP type_NN ._SENT Given_VBN that_DT instances_NNS of_IN discordant_JJ results_NNS for_IN HPV_NP DNA_NP detection_NN between_IN the_DT urine_NN specimens_NNS and_CC the_DT cervical_JJ swab_NN specimens_NNS may_MD potentially_RB be_VB rectified_VBN by_IN testing_VBG multiple_JJ urine_NN specimens_NNS from_IN the_DT same_JJ patient_NN ,_, the_DT urine_NN assay_NN merits_VBZ further_JJR study_NN to_TO assess_VB whether_IN it_PP may_MD be_VB an_DT appropriate_JJ cervical_JJ cancer_NN screening_NN technique_NN for_IN HIV-positive_JJ women_NNS ._SENT Primary_JJ screening_NN of_IN HIV-positive_JJ women_NNS could_MD involve_VB the_DT identification_NN of_IN patients_NNS infected_VBN with_IN high-risk_JJ HPV_NP types_NNS by_IN urine_NN assay_NN and_CC then_RB monitoring_VBG of_IN these_DT patients_NNS more_RBR closely_RB by_IN use_NN of_IN Pap_NN smears_NNS (_( every_DT 6_CD months_NNS )_) ._SENT In_IN addition_NN ,_, this_DT assay_NN could_MD potentially_RB be_VB used_VBN as_IN a_DT secondary_JJ screen_NN for_IN those_DT HIV-positive_JJ women_NNS with_IN abnormal_JJ Pap_NN smears_NNS to_TO monitor_VB the_DT course_NN of_IN their_PP$ HPV_NP infections_NNS ._SENT Additional_JJ studies_NNS need_VBP to_TO be_VB performed_VBN in_IN order_NN to_TO solidify_VB the_DT role_NN of_IN urine_NN screening_NN in_IN the_DT HIV-positive_JJ population_NN ._SENT Future_JJ studies_NNS also_RB need_VBP to_TO be_VB undertaken_VBN to_TO ascertain_VB the_DT role_NN of_IN testing_NN of_IN urine_NN for_IN HPV_NP DNA_NP in_IN women_NNS not_RB infected_VBN with_IN HIV_NP ._SENT 